Oculis Achieves Positive FDA Pre-IND Outcome for Privosegtor Program
ZUG, Switzerland, Aug. 3, 2026 Oculis announced that the U.S. Food and Drug Administration (FDA) has provided positive pre-Investigational...
Phase 2
Advertisement
Moleculin Reports Positive Interim MIRACLE Trial Data in Venetoclax-Failed AML Patients
HOUSTON, July 31, 2026 Moleculin Biotech, Inc. announced updated positive preliminary blinded interim results from Part A of its...
Caldera, Synlogic Unite in $278M Biotech Merger
CAMBRIDGE, Mass., July 29, 2026 Synlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive all-stock merger agreement...
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder
GAITHERSBURG, Md., July 28, 2026 Altimmune, Inc. announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating...
Advertisements
Verastem Oncology Doses First Patient in Phase 2 VS-7375 NSCLC Trial
BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...
Celldex Reports Phase 2 Barzolvolimab Results in Prurigo Nodularis
HAMPTON, N.J., July 21, 2026 Celldex announced topline results from its Phase 2 clinical trial evaluating barzolvolimab in patients...
Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
Acadia Secures FDA Fast Track for Alzheimer’s Psychosis Drug
San Diego, California, USA | July 21, 2026 Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)...
Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
Advertisement
